{"id":"W4407700377","doi":"10.1200/jco.2025.43.5_suppl.552","title":"KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) and novel immunotherapy agents for advanced clear cell renal cell carcinoma (ccRCC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Renal cell carcinoma; Clear cell renal cell carcinoma; Immunotherapy; Internal medicine; Oncology; Cancer research; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005419153,0.001223473,0.003032221,0.0006451787,0.0009623331,0.001365922,0.001495511,0.002053763,0.005935693],"category_scores_gemma":[0.002492596,0.0006944527,0.002179912,0.001467585,0.0006278424,0.001240485,0.0007343884,0.002250219,0.001527825],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001653617,"about_ca_system_score_gemma":0.001974927,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003038058,"about_ca_topic_score_gemma":0.01502887,"domain_scores_codex":[0.9976149,0.001523627,0.0001922102,0.0002021254,0.0001821475,0.0002850645],"domain_scores_gemma":[0.9980847,0.0004132493,0.0006347132,0.0001602757,0.0001416506,0.0005653045],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.8516461,0.008720446,0.03750171,0.003453055,0.007379736,0.000224253,0.0002128606,0.001000787,0.00868468,0.0003510012,0.02063281,0.06019263],"study_design_scores_gemma":[0.7380686,0.1359197,0.08588967,0.0004245193,0.01072368,0.0007161926,0.000135171,0.0008363344,0.003909587,0.0003849626,0.02292601,0.00006548935],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.906705,0.04163884,0.001086242,0.001661768,0.000854494,0.01186449,0.02472448,0.0002738322,0.01119087],"genre_scores_gemma":[0.9618185,0.006393157,0.001597386,0.002404378,0.0007501232,0.00882594,0.01525585,0.00006301644,0.002891689],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005935693,"threshold_uncertainty_score":0.02865952,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09398857896513756,"score_gpt":0.4303186639082325,"score_spread":0.336330084943095,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}